ANAB: AnaptysBio, Inc.
Performance
ANAB +65.15%
Watchlist
Select an item
Summary
ANAB at a glance
ANAB returned +65.15% over the past year and +12.02% a year over five years. Its worst drop in that year was -34.92%, smaller than 47% of stocks on Redstone, and its Sharpe ratio of 1.07 beats 78% of stocks on Redstone. It pays no dividends.
Current Drawdown
-31.28%
Rolling Volatility
52.47%
Actions
Metrics
Risk Indicators
Alpha56.56%
Beta0.92x
Sharpe1.07
Sortino1.60
Omega1.21
Calmar1.87
Martin3.93
Profile
About ANAB
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.4B
- Listed
- Jan 2017
- Employees
- 104
- Headquarters
- San Diego, CA
- Website
- anaptysbio.com
Comparisons